UPDATE FROM THE PHASE 2 RESTORE TRIAL OF ELRITERCEPT IN PATIENTS WITH MYELOFIBROSIS RECEIVING RUXOLITINIB (SIE 2026) - Oct 6, 2026 - Abstract #DP100; Pres time: Sep 21, 2026; 07:00 PM - 08:00 PM; Location: AREA POSTER; P2 | "Reused with permission. This abstract was previously accepted and presented at the 2026 EHA Annual Meeting."
Clinical • P2 data • Hematological Disorders • Myelofibrosis • Thrombocytopenia • ACVR2A • JAK2 • TGFB1
|
|
A. Iurlo1; C. Rinaldi2; D. Ross3; L. Chee4; C. Teh5; F. Palandri6; M. Fox7; J. O'Sullivan8; M. Brociner9; X. Tong10; V. Sundaresan10; Z. Yu10; L. Sellner10; K. Togami10; C. Harrison8
|